Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $38
Verona Pharma plc Sponsored ADR -2.22% Pre
Verona Pharma plc Sponsored ADR VRNA | 33.11 33.11 | -2.22% 0.00% Pre |
Truist Securities analyst Joon Lee maintains Verona Pharma (NASDAQ:
VRNA) with a Buy and raises the price target from $32 to $38.